Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NBIX

Neurocrine Biosciences Inc

163.41

Aug 07 • 3:59 PM ET +3.59 (2.25%)

163.41

Aftermarket • 7:34 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Large NASD

Aug 07, 8:35 AMNeurocrine Biosciences starts first-in-human Phase 1 trial of NBIP-'1968, a once-weekly GLP-1/GIP/glucagon triple agonist for obesity

Peers: JAZZ ALNY RPRX EXEL INCY BMRN IONS VRTX LGND CRSP

| Held by: IJH VTI VB VBK VXF MDY IBB XBI XMHQ IJK

Index	-
Market Cap	16.61B
Enterprise Value	16.62B
Income	705.50M
Sales	3.37B
Book/sh	36.35
Cash/sh	3.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2000
IPO	May 23, 1996

P/E	23.94
Forward P/E	16.68
PEG	0.43
P/S	4.92
P/B	4.49
P/C	42.61
P/FCF	20.46
EV/EBITDA	19.48
EV/Sales	4.93
Quick Ratio	1.75
Current Ratio	1.87
Debt/Eq	0.11
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	6.83
EPS next Y	9.79
EPS next Q	1.92
EPS this Y	53.73%
EPS next Y	36.43%
EPS next 5Y	38.87%
EPS past 3/5Y	44.05% 2.31%
Sales past 3/5Y	24.32% 22.29%
EPS Y/Y TTM	102.44%
Sales Y/Y TTM	34.42%
EPS Q/Q	30.20%
Sales Q/Q	39.49%
Earnings	Jul 30 AMC
EPS/Sales Surpr.	-15.73% 7.61%

Insider Own	1.74%
Insider Trans	-18.27%
Inst Own	101.85%
Inst Trans	2.26%
ROA	15.26%
ROE	22.09%
ROIC	17.23%
Gross Margin	97.48%
Oper. Margin	23.90%
Profit Margin	20.91%
SMA20	-5.12%
SMA50	-2.80%
SMA200	11.52%
Trades

Shs Outstand	101.60M
Shs Float	99.88M
Short Float	5.34%
Short Ratio	4.20
Short Interest	5.33M
52W High	186.12 -12.20%
52W Low	122.14 33.79%
Volatility	3.28% 3.55%
ATR (14)	6.00
RSI (14)	42.64
Beta	0.38
Rel Volume	0.76
Avg Volume	1.27M
Volume	971,005

Perf Week	-2.03%
Perf Month	-9.49%
Perf Quarter	9.24%
Perf Half Y	18.47%
Perf YTD	15.22%
Perf Year	30.10%
Perf 3Y	61.36%
Perf 5Y	82.44%
Perf 10Y	227.02%
Recom	1.42
Target Price	211.77
Prev Close	159.82
Price	163.41
Change %	2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Resumed	Goldman	Buy	$213
May-22-26	Initiated	Bernstein	Outperform	$221
Feb-24-26	Initiated	Wolfe Research	Outperform	$160
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145

Show Previous Ratings

Aug-07-26 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist (PR Newswire)
Aug-06-26 09:40AM	StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It (TMX Newsfile)
Jul-31-26 01:05AM	Neurocrine Biosciences Inc (NBIX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com) -10.08%
Jul-30-26 10:53PM	Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary (Moby)
04:12PM	Neurocrine: Q2 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results (PR Newswire)
Jul-23-26 04:05PM	Neurocrine Biosciences Announces Key Leadership Hiring, Promotions (PR Newswire)
Jul-21-26 04:05PM	Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer (PR Newswire)
Jul-10-26 11:58AM	Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline (FX Empire)
Jul-09-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results (PR Newswire)
Jul-01-26 04:05PM	Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia (PR Newswire)
Jun-15-26 04:10PM	Soleno Therapeutics Presents New VYKAT XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period (PR Newswire)
04:05PM	Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11ß-Hydroxylase Deficiency at ENDO 2026 (PR Newswire)
08:35AM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 (PR Newswire)
04:05PM	Loading…
Jun-08-26 04:05PM	Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA (valbenazine) Capsules Across a Broad Range of Patients (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities (PR Newswire)
Jun-03-26 08:30AM	Neurocrine Biosciences to Present New Two-Year CRENESSITY (crinecerfont) Data on Key Clinical and Patient-Reported Outcome Measures at ENDO 2026 (PR Newswire) +6.63%
Jun-02-26 09:43AM	Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls (The Fly)
01:30AM	Centene, Deckers and 14 Other 'Dividend Hopefuls' (Barrons.com)
May-26-26 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in June (PR Newswire)
May-20-26 12:44PM	Neurocrine Biosciences Hits New Highs On Earnings Surge (Investor's Business Daily)
May-18-26 04:05PM	Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA (valbenazine) Capsules (PR Newswire)
08:46AM	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics (PR Newswire)
May-15-26 01:32PM	CrowdStrike Leads This Group Of Four Stocks To New Highs (Investor's Business Daily)
May-06-26 08:30AM	Neurocrine Biosciences, Inc. Q1 2026 Earnings Call Summary (Moby) +8.86%
08:30AM	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia (PR Newswire)
May-05-26 04:14PM	Neurocrine: Q1 Earnings Snapshot (Associated Press)
04:01PM	Neurocrine Biosciences Reports First-Quarter 2026 Financial Results (PR Newswire)
09:00AM	Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 (PR Newswire)
08:30AM	Loading…
May-04-26 08:30AM	Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist (PR Newswire)
May-01-26 04:05PM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia (PR Newswire)
Apr-29-26 04:05PM	Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale (PR Newswire)
Apr-22-26 04:05PM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia (PR Newswire)
Apr-14-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results (PR Newswire)
08:30AM	Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA (valbenazine) Capsules Compared to AUSTEDO XR (PR Newswire)
Apr-07-26 09:47AM	Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls (The Fly)
05:21AM	Neurocrine to acquire Soleno in $2.9bn transaction (Hospital Management)
12:01AM	Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal (The Daily Upside)
Apr-06-26 04:06PM	Oil Climbs, Stocks Whipsaw After Trumps Warning: Markets Wrap (Bloomberg)
03:28PM	Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium (GuruFocus.com)
09:35AM	Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal (Proactive)
08:58AM	SLNO Jumps As Deal Buzz Lifts Stocks (GuruFocus.com)
07:34AM	Neurocrine to Buy Soleno for $2.9 Billion (The Wall Street Journal)
07:24AM	This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. (Barrons.com)
07:18AM	Soleno Therapeutics climbs on deal news, and more stocks on the move (MarketWatch)
07:04AM	Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move. (MarketWatch)
07:00AM	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio (PR Newswire)
Mar-26-26 08:30AM	Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings (PR Newswire)
Mar-17-26 04:05PM	Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer (PR Newswire)
Mar-10-26 04:01PM	Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum (PR Newswire)
Mar-06-26 05:00PM	BetterInvesting Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) (PR Newswire)
Feb-27-26 09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Feb-24-26 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March (PR Newswire)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Dominos Pizza, KeyCorp, Qualcomm, and More (24/7 Wall St.)
Feb-23-26 04:28PM	Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update (Insider Monkey)
Feb-18-26 09:33PM	Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza (Insider Monkey)
04:19AM	New Strong Sell Stocks for February 18th (Zacks)
Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

PresidentMr. Kyle W. Gano Ph.D.

Chief Financial OfficerMr. Matthew C. Abernethy CPA

Chief Scientific OfficerDr. Jude Onyia Ph.D.

Chief Commercial OfficerMr. Eric S. Benevich

Strategic AdvisorDr. Eiry Wyn Roberts M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norwalk Leslie V	Director	Jul 29 '26	Option Exercise	139.43	842	117,400	2,430	Jul 30 05:29 PM
Norwalk Leslie V	Director	Jul 28 '26	Sale	182.01	1,250	227,508	1,588	Jul 30 05:29 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '26	Option Exercise	106.02	4,367	462,989	20,592	Jul 13 04:27 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '26	Sale	181.02	4,367	790,514	16,225	Jul 13 04:27 PM
Lippoldt Darin	Chief Legal Officer	Jul 09 '26	Option Exercise	81.49	10,000	814,900	64,729	Jul 13 04:27 PM
Lippoldt Darin	Chief Legal Officer	Jul 09 '26	Sale	179.60	10,000	1,796,014	54,729	Jul 13 04:27 PM
INGRID DELAET	Officer	Jul 10 '26	Proposed Sale	180.55	4,367	788,462		Jul 10 04:39 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 09 '26	Option Exercise	103.52	8,433	872,984	24,658	Jul 09 06:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 07 '26	Option Exercise	103.52	3,401	352,072	19,626	Jul 09 06:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 08 '26	Option Exercise	103.52	2,737	283,334	18,962	Jul 09 06:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 09 '26	Sale	178.72	8,433	1,507,135	16,225	Jul 09 06:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 07 '26	Sale	178.57	3,401	607,305	16,225	Jul 09 06:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 08 '26	Sale	178.54	2,737	488,672	16,225	Jul 09 06:41 PM
DARIN LIPPOLDT	Officer	Jul 09 '26	Proposed Sale	178.24	10,000	1,782,400		Jul 09 04:27 PM
INGRID DELAET	Officer	Jul 07 '26	Proposed Sale	174.10	14,571	2,536,811		Jul 07 04:33 PM
Lippoldt Darin	Chief Legal Officer	Jun 29 '26	Option Exercise	81.49	9,800	798,602	62,839	Jun 30 04:52 PM
Lippoldt Darin	Chief Legal Officer	Jun 26 '26	Option Exercise	81.49	200	16,298	54,929	Jun 30 04:52 PM
Lippoldt Darin	Chief Legal Officer	Jun 29 '26	Sale	170.16	9,800	1,667,579	54,729	Jun 30 04:52 PM
Lippoldt Darin	Chief Legal Officer	Jun 26 '26	Sale	169.56	200	33,913	54,729	Jun 30 04:52 PM
DARIN LIPPOLDT	Officer	Jun 29 '26	Proposed Sale	168.52	9,800	1,651,496		Jun 29 04:43 PM
DARIN LIPPOLDT	Officer	Jun 26 '26	Proposed Sale	164.18	200	32,836		Jun 26 04:25 PM
SHERWIN STEPHEN A	Director	Jun 05 '26	Option Exercise	64.10	25,000	1,602,500	40,860	Jun 09 05:40 PM
SHERWIN STEPHEN A	Director	Jun 05 '26	Sale	165.32	25,000	4,132,969	15,860	Jun 09 05:40 PM
Norwalk Leslie V	Director	Jun 04 '26	Sale	168.06	1,250	210,072	2,838	Jun 08 06:07 PM
STEPHEN SHERWIN	Director	Jun 05 '26	Proposed Sale	167.35	25,000	4,183,750		Jun 05 04:31 PM
Cooke Julie	Chief Human Resources Officer	Jun 02 '26	Option Exercise	81.49	24,965	2,034,398	59,311	Jun 04 06:02 PM
Cooke Julie	Chief Human Resources Officer	Jun 02 '26	Sale	156.22	36,937	5,770,235	22,374	Jun 04 06:02 PM
Keswani Sanjay Chandru	Chief Medical Officer	Jun 02 '26	Option Exercise	0.00	3,212	0	3,212	Jun 04 05:54 PM
Onyia Jude	Chief Scientific Officer	Jun 01 '26	Option Exercise	84.74	11,000	932,140	36,846	Jun 02 06:08 PM
Onyia Jude	Chief Scientific Officer	Jun 01 '26	Sale	160.25	11,000	1,762,710	25,846	Jun 02 06:08 PM
Delaet Ingrid	Chief Regulatory Officer	May 29 '26	Option Exercise	79.02	2,261	178,664	18,486	Jun 02 06:03 PM
Delaet Ingrid	Chief Regulatory Officer	May 29 '26	Sale	156.71	2,261	354,321	16,225	Jun 02 06:03 PM
JULIE COOKE	Officer	Jun 02 '26	Proposed Sale	161.00	36,937	5,946,857		Jun 02 04:39 PM
JUDE ONYIA	Officer	Jun 01 '26	Proposed Sale	158.30	11,000	1,741,300		Jun 01 04:25 PM
Onyia Jude	Chief Scientific Officer	May 27 '26	Option Exercise	84.74	11,000	932,140	36,846	May 29 06:09 PM
Onyia Jude	Chief Scientific Officer	May 27 '26	Sale	155.53	11,000	1,710,865	25,846	May 29 06:09 PM
INGRID DELAET	Officer	May 29 '26	Proposed Sale	156.39	2,261	353,598		May 29 04:25 PM
Boyer David W.	Chief Corp. Affairs Officer	May 26 '26	Sale	156.64	3,888	609,023	7,799	May 28 06:08 PM
JUDE ONYIA	Officer	May 27 '26	Proposed Sale	155.73	11,000	1,713,030		May 27 04:33 PM
DAVID WARREN BOYER	Officer	May 26 '26	Proposed Sale	156.70	3,888	609,250		May 26 04:45 PM
SHERWIN STEPHEN A	Director	May 21 '26	Option Exercise	0.00	3,318	0	15,860	May 21 07:24 PM
Sharp Shalini	Director	May 21 '26	Option Exercise	0.00	1,659	0	4,088	May 21 07:24 PM
RASTETTER WILLIAM H	Director	May 21 '26	Option Exercise	0.00	3,318	0	43,678	May 21 07:24 PM
POPS RICHARD F	Director	May 21 '26	Option Exercise	0.00	3,318	0	37,798	May 21 07:23 PM
POON CHRISTINE A	Director	May 21 '26	Option Exercise	0.00	3,318	0	4,753	May 21 07:22 PM
Norwalk Leslie V	Director	May 21 '26	Option Exercise	0.00	1,659	0	4,088	May 21 07:22 PM
MORROW GEORGE J	Director	May 21 '26	Option Exercise	0.00	3,318	0	10,386	May 21 07:21 PM
Mercier Johanna	Director	May 21 '26	Option Exercise	0.00	3,318	0	6,853	May 21 07:21 PM
LYONS GARY A	Director	May 21 '26	Option Exercise	0.00	1,659	0	122,141	May 21 07:21 PM
GORMAN KEVIN CHARLES	Director	May 19 '26	Option Exercise	43.24	205,088	8,868,005	756,381	May 21 05:49 PM
GORMAN KEVIN CHARLES	Director	May 19 '26	Sale	154.33	245,088	37,824,872	511,293	May 21 05:49 PM
KEVIN CHARLES GORMAN	Director	May 19 '26	Proposed Sale	157.21	245,088	38,530,284		May 19 04:31 PM
POPS RICHARD F	Director	May 15 '26	Option Exercise	47.89	15,000	718,350	49,480	May 18 05:50 PM
POPS RICHARD F	Director	May 15 '26	Sale	157.65	15,000	2,364,760	34,480	May 18 05:50 PM
RICHARD F POPS	Director	May 15 '26	Proposed Sale	159.05	15,000	2,385,750		May 15 04:33 PM
Norwalk Leslie V	Director	May 12 '26	Sale	155.01	3,810	590,601	2,429	May 14 04:45 PM
Norwalk Leslie V	Director	May 12 '26	Proposed Sale	162.92	6,310	1,028,050		May 12 02:35 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '26	Option Exercise	0.00	4,807	0	41,676	Feb 17 05:49 PM
ABERNETHY MATT	Chief Financial Officer	Feb 12 '26	Option Exercise	0.00	2,133	0	39,230	Feb 17 05:49 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '26	Option Exercise	0.00	3,352	0	7,969	Feb 17 05:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 12 '26	Option Exercise	0.00	1,600	0	6,313	Feb 17 05:48 PM
Gano Kyle	Chief Executive Officer	Feb 13 '26	Option Exercise	0.00	4,807	0	147,610	Feb 17 05:48 PM
Gano Kyle	Chief Executive Officer	Feb 12 '26	Option Exercise	0.00	4,907	0	146,661	Feb 17 05:48 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '26	Option Exercise	0.00	5,407	0	21,066	Feb 17 05:47 PM
Onyia Jude	Chief Scientific Officer	Feb 12 '26	Option Exercise	0.00	2,560	0	18,537	Feb 17 05:47 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '26	Option Exercise	0.00	4,044	0	56,664	Feb 17 05:46 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 12 '26	Option Exercise	0.00	2,005	0	54,760	Feb 17 05:46 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '26	Option Exercise	0.00	2,911	0	30,395	Feb 17 05:46 PM
Cooke Julie	Chief Human Resources Officer	Feb 12 '26	Option Exercise	0.00	1,387	0	28,989	Feb 17 05:46 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	4,100	0	51,628	Feb 17 05:45 PM
Lippoldt Darin	Chief Legal Officer	Feb 12 '26	Option Exercise	0.00	1,792	0	49,584	Feb 17 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '26	Option Exercise	0.00	2,760	0	7,779	Feb 17 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 12 '26	Option Exercise	0.00	1,600	0	6,656	Feb 17 05:45 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '26	Option Exercise	0.00	10,981	0	524,850	Feb 17 05:44 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM

Open in Screener

XNCR

Xencor Inc

20.81

Aug 07 • 3:59 PM ET +0.81 (4.05%)

21.22

Aftermarket • 7:34 PM ET +0.41 (1.96%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR BMRN CRNX RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: IJR XBI VTI IWM SPSM VXF IJS IWN IBB SLYV

Index	RUT
Market Cap	1.55B
Enterprise Value	1.26B
Income	-163.32M
Sales	104.97M
Book/sh	6.77
Cash/sh	6.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	260
IPO	Dec 03, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	14.74
P/B	3.07
P/C	3.39
P/FCF	-
EV/EBITDA	-
EV/Sales	12.01
Quick Ratio	6.39
Current Ratio	6.39
Debt/Eq	0.34
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-3.26
EPS next Q	-0.31
EPS this Y	-145.19%
EPS next Y	-7.31%
EPS next 5Y	-
EPS past 3/5Y	-10.21% -0.43%
Sales past 3/5Y	-8.62% 0.47%
EPS Y/Y TTM	10.25%
Sales Y/Y TTM	-28.56%
EPS Q/Q	30.99%
Sales Q/Q	17.46%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	63.82% 171.16%

Insider Own	5.89%
Insider Trans	-1.80%
Inst Own	112.07%
Inst Trans	-4.03%
ROA	-20.36%
ROE	-29.07%
ROIC	-25.44%
Gross Margin	90.30%
Oper. Margin	-205.84%
Profit Margin	-155.59%
SMA20	10.67%
SMA50	33.24%
SMA200	49.17%
Trades

Shs Outstand	74.33M
Shs Float	69.98M
Short Float	15.49%
Short Ratio	11.73
Short Interest	10.84M
52W High	21.96 -5.24%
52W Low	6.92 200.72%
Volatility	6.85% 7.80%
ATR (14)	1.33
RSI (14)	66.09
Beta	0.83
Rel Volume	1.22
Avg Volume	924.17K
Volume	1,124,578

Perf Week	2.97%
Perf Month	29.13%
Perf Quarter	69.05%
Perf Half Y	92.33%
Perf YTD	35.92%
Perf Year	184.29%
Perf 3Y	-14.22%
Perf 5Y	-33.34%
Perf 10Y	-7.26%
Recom	1.36
Target Price	29.00
Prev Close	20.00
Price	20.81
Change %	4.05%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Downgrade	JP Morgan	Overweight → Neutral	$13
Nov-24-25	Initiated	Truist	Buy
Oct-29-25	Upgrade	Barclays	Underweight → Overweight	$23
Sep-17-25	Resumed	Barclays	Underweight	$6
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$12
Apr-21-25	Initiated	William Blair	Outperform
Dec-12-24	Initiated	Wells Fargo	Overweight	$37
Dec-02-24	Upgrade	Piper Sandler	Neutral → Overweight	$20 → $30
Apr-16-24	Reiterated	BTIG Research	Buy	$56 → $38
Feb-28-24	Downgrade	Piper Sandler	Overweight → Neutral	$37 → $24
May-19-23	Initiated	BofA Securities	Buy	$42
Dec-06-22	Initiated	Cowen	Outperform
Oct-13-22	Upgrade	Raymond James	Outperform → Strong Buy	$58
Sep-21-22	Initiated	JP Morgan	Overweight	$37
Jul-06-22	Resumed	Canaccord Genuity	Buy	$50
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$54
Jan-21-22	Initiated	SMBC Nikko	Outperform	$60
Dec-15-21	Initiated	H.C. Wainwright	Buy	$61
Oct-15-21	Resumed	BTIG Research	Buy	$56
Feb-24-21	Upgrade	Raymond James	Mkt Perform → Outperform	$58

Show Previous Ratings

Aug-05-26 04:19PM	Xencor: Q2 Earnings Snapshot (Associated Press)
04:01PM	Xencor Reports Second Quarter 2026 Financial Results (Business Wire)
Jul-29-26 04:01PM	Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter (Business Wire) +10.04%
Jul-17-26 09:11AM	Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +16.86%
Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
06:40PM	Loading…
Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
May-18-26 08:34AM	The Biology Came First. (Business Wire)
May-06-26 04:08PM	Xencor: Q1 Earnings Snapshot (Associated Press) -5.38%
04:01PM	Xencor Reports First Quarter 2026 Financial Results (Business Wire)
May-04-26 08:01AM	Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW (Business Wire) +5.28%
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 06:00AM	Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor (Benzinga) -12.40%
Mar-04-26 04:01PM	Xencor Announces Change to Ultomiris Royalty Revenue Forecast (Business Wire) +5.99%
Feb-25-26 08:05PM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +13.11%
04:19PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Xencor Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-23-26 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-26 12:24AM	Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage (Insider Monkey)
Jan-08-26 08:01AM	Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones (Business Wire) -5.08%
Dec-09-25 07:00AM	Xencor Announces Extension of U.S. Patent Term on Certain Xtend Antibodies (Business Wire)
Nov-10-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire) +8.22%
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2025 Financial Results (Business Wire)
06:08AM	Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner (TipRanks)
Nov-04-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-24-25 12:30PM	Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma (Business Wire) +7.05%
Oct-21-25 08:01AM	Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily) +6.03%
12:45PM	Loading…
Oct-14-25 12:45PM	Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire) -10.96%
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
Sep-18-25 10:05AM	Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks) +8.43%
Sep-08-25 12:30AM	RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating (Insider Monkey)
Aug-27-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Aug-08-25 09:05AM	Xencor price target lowered to $26 from $31 at Wedbush (TipRanks)
Aug-06-25 05:35PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.79%
04:36PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 04:01PM	Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors (Business Wire)
07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
May-07-25 05:30PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.61% +10.08%
04:26PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports First Quarter 2025 Financial Results (Business Wire)
May-01-25 10:01AM	Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-29-25 04:01PM	Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease (Business Wire)
Apr-11-25 10:15AM	Xencor, Inc.: No Major Near Term Catalysts (Seeking Alpha) +7.83%
Apr-10-25 12:00PM	Xencor (XNCR) Upgraded to Buy: Here's Why (Zacks) -10.10%
Mar-13-25 04:01PM	Xencor Appoints Todd Simpson to Board of Directors (Business Wire)
Feb-27-25 09:15AM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
08:01AM	Xencor Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 09:35AM	Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-21-25 09:35AM	Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround (Zacks) +6.29%
Jan-20-25 09:35AM	After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) (Zacks)
Jan-15-25 09:35AM	Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks (Zacks)
Jan-14-25 12:00PM	Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -5.68%
Dec-12-24 12:00PM	All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy (Zacks)
Dec-04-24 09:55AM	Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet (Zacks)
Nov-26-24 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Nov-18-24 09:55AM	Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade (Zacks)
Nov-14-24 09:55AM	Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-06-24 05:15PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.39%
04:11PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 07:00AM	Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease (Business Wire)
Nov-01-24 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? (Zacks)
Oct-29-24 10:01AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Xencor Inc Holdings (GuruFocus.com)
Oct-16-24 09:55AM	Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know (Zacks)
Oct-10-24 08:09AM	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Business Wire)
Oct-04-24 08:01AM	Xencor Announces Upcoming Change to Board of Directors (Business Wire)
Sep-12-24 04:01PM	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
04:55AM	Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? (Zacks)
Sep-11-24 06:31AM	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Business Wire) +10.45%
Sep-10-24 04:01PM	Xencor Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-09-24 07:31AM	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Business Wire) +22.93%
Sep-06-24 08:01AM	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Business Wire)
Aug-05-24 09:55PM	XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) -7.30%
05:15PM	Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2024 Financial Results (Business Wire)
Jun-13-24 08:01AM	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Business Wire)
May-10-24 01:45PM	Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
06:20AM	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating (MT Newswires)
May-09-24 11:54PM	XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	Xencor Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 10:00AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-03-24 07:01PM	Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares (GuruFocus.com)
May-02-24 03:31AM	Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? (Zacks)
Apr-09-24 08:01AM	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Business Wire)
Mar-08-24 05:01PM	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Mar-07-24 05:00PM	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Feb-28-24 04:01PM	Xencor to Present at Upcoming Investor Conferences (Business Wire) -14.06%
09:35AM	Q4 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
08:38AM	Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:20PM	Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:26PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Co-FounderDr. Bassil I. Dahiyat Ph.D.

Senior VP & CFOMr. Bart Jan Cornelissen

Executive VP of Research & Chief Scientific OfficerDr. John R. Desjarlais Ph.D.

Senior VPMs. Celia E. Eckert J.D.

Associate Director and Head of Corporate Communications & Investor RelationsMr. Charles Liles

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feigal Ellen	Director	Jun 18 '26	Sale	13.06	6,843	89,370	12,340	Jun 22 04:01 PM
Feigal Ellen	Director	Jun 18 '26	Proposed Sale	13.06	6,843	89,370		Jun 18 09:38 AM
GORMAN KEVIN CHARLES	Director	Jun 15 '26	Sale	12.31	7,527	92,657	11,378	Jun 17 04:02 PM
GUSTAFSON KURT A	Director	Jun 15 '26	Sale	12.31	5,474	67,385	14,709	Jun 17 04:01 PM
RANIERI RICHARD J	Director	Jun 15 '26	Sale	12.31	5,474	67,385	13,709	Jun 17 04:01 PM
Montgomery Alan Bruce	Director	Jun 15 '26	Sale	12.31	5,064	62,338	15,547	Jun 17 04:01 PM
Montgomery Alan Bruce	Director	Jun 15 '26	Proposed Sale	12.31	5,064	62,338		Jun 15 11:36 AM
RANIERI RICHARD J	Director	Jun 15 '26	Proposed Sale	12.31	5,474	67,385		Jun 15 10:57 AM
GUSTAFSON KURT A	Director	Jun 15 '26	Proposed Sale	12.31	5,474	67,385		Jun 15 10:44 AM
GORMAN KEVIN CHARLES	Director	Jun 15 '26	Proposed Sale	12.31	7,527	92,657		Jun 15 09:44 AM
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Apr 10 '26	Sale	12.29	3,499	42,990	75,898	Apr 13 04:01 PM
Cornelissen Bart Jan	Officer	Apr 10 '26	Proposed Sale	12.29	3,499	42,990		Apr 10 03:16 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 05 '26	Sale	11.25	4,118	46,309	266,333	Mar 09 04:07 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 06 '26	Sale	11.02	2,502	27,571	263,831	Mar 09 04:07 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 05 '26	Sale	11.25	3,244	36,480	78,685	Mar 09 04:06 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 06 '26	Sale	11.02	1,767	19,472	76,918	Mar 09 04:06 PM
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Mar 05 '26	Sale	11.25	2,517	28,305	79,397	Mar 09 04:06 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 05 '26	Sale	11.25	14,870	167,221	552,922	Mar 09 04:06 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 06 '26	Sale	11.02	6,606	72,796	546,316	Mar 09 04:06 PM
Eckert Celia	Officer	Mar 06 '26	Proposed Sale	11.02	1,767	19,472		Mar 06 04:00 PM
Dahiyat Bassil I	Officer	Mar 06 '26	Proposed Sale	11.02	6,606	72,796		Mar 06 03:55 PM
Desjarlais John R	Officer	Mar 06 '26	Proposed Sale	11.02	2,502	27,571		Mar 06 03:39 PM
Eckert Celia	Officer	Mar 05 '26	Proposed Sale	11.25	3,244	36,480		Mar 05 04:30 PM
Dahiyat Bassil I	Officer	Mar 05 '26	Proposed Sale	11.25	14,870	167,221		Mar 05 04:26 PM
Cornelissen Bart Jan	Officer	Mar 05 '26	Proposed Sale	11.25	2,517	28,305		Mar 05 04:18 PM
Desjarlais John R	Officer	Mar 05 '26	Proposed Sale	11.25	4,118	46,309		Mar 05 04:14 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 03 '26	Sale	11.90	2,663	31,677	270,451	Mar 04 07:43 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 03 '26	Sale	11.90	1,492	17,747	81,929	Mar 04 07:42 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 03 '26	Sale	11.90	6,758	80,387	567,792	Mar 04 07:42 PM
Dahiyat Bassil I	Officer	Mar 03 '26	Proposed Sale	11.90	6,758	80,387		Mar 03 04:27 PM
Eckert Celia	Officer	Mar 03 '26	Proposed Sale	11.90	1,492	17,747		Mar 03 03:32 PM
Desjarlais John R	Officer	Mar 03 '26	Proposed Sale	11.90	2,663	31,677		Mar 03 03:15 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jan 23 '26	Option Exercise	12.51	5,322	66,578	248,207	Jan 26 04:01 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Option Exercise	12.51	73,367	917,821	309,941	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 22 '25	Option Exercise	12.51	6,311	78,951	242,885	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Sale	15.72	73,367	1,153,329	236,574	Dec 23 04:02 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Option Exercise	12.51	114,377	1,430,856	581,012	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 22 '25	Option Exercise	12.51	10,624	132,906	477,259	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Sale	15.71	114,377	1,796,863	466,635	Dec 23 04:01 PM
Desjarlais John R	Officer	Dec 19 '25	Proposed Sale	15.72	73,367	1,153,517		Dec 19 04:19 PM
Dahiyat Bassil I	Officer	Dec 19 '25	Proposed Sale	15.71	114,377	1,796,943		Dec 19 04:13 PM

NBIX

Neurocrine Biosciences Inc

XNCR

Xencor Inc

Upgrade your Finviz experience